8-K ·Filed May 29, 2026

EXEL

EXELIXIS, INC.
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago SEC0000939767-26-000074
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine annual meeting results with no surprises. The 2M share increase to the equity plan is small relative to market cap and standard for ongoing compensation. No trading catalyst here — monitor next quarterly earnings for fundamental performance.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
EXEL ▲ +12.59% at T+60d
NEUTRAL call ✓ call won +12.59% · α vs SPY +11.62% · entry $50.20 → $56.52
Entry anchored
May 29, 2026
via day open
T+1d
-3.41%
call -3.41% · α -3.55%
$48.49
settled 4mo ago
T+5d
+4.98%
call +4.98% · α +7.73%
$52.70
settled 4mo ago
T+20d
+8.13%
call +8.13% · α +10.44%
$54.28
settled 3mo ago
T+60d
+12.59%
call +12.59% · α +11.62%
$56.52
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Exelixis held its 2026 Annual Meeting on May 26, 2026, where stockholders approved the amendment and restatement of the 2017 Equity Incentive Plan, adding 2,000,000 new shares to the share reserve, and ratified the selection of Ernst & Young as independent auditor. All 11 director nominees were elected, and the advisory Say on Pay proposal passed. This is a routine governance filing with no material financial impact.

Key Facts

  • Stockholders approved the amendment and restatement of the 2017 Equity Incentive Plan, adding 2,000,000 new shares to the share reserve (total share reserve now 75,953,064 shares).
  • All 11 director nominees were elected with strong support (lowest 'for' vote was 180,367,648 for Maria C. Freire).
  • Ratification of Ernst & Young as independent auditor passed with 222,343,120 votes for.
  • Advisory Say on Pay proposal passed with 163,104,135 votes for (43,156,553 against).
  • No departures, appointments, or changes to executive compensation were reported.

Financial Impact

2,000,000 new shares authorized for equity grants, representing approximately 0.6% of shares outstanding based on a $12.9B market cap — minimal dilution.

dilution

Risk Factors

  • Say on Pay received 20.9% against votes (43.2M), which is notable but non-binding and below typical threshold for concern.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
58% bullish (26 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000939767-26-000074
Exhibit: exel-20260526.htm0000939767-26-000074
Document: 0000939767-26-000074-index-headers.html0000939767-26-000074
Document: 0000939767-26-000074-index.html0000939767-26-000074
Document: 0000939767-26-000074.txt0000939767-26-000074
12 reports for EXEL
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +21.97%Feb 28, 2026
Filters
Rows
Reports for EXEL — sortable, filterable
TypeNow
Sep 11, 2026
21d ago
8-K
BEARISH ★ 6/10
$56.12 $58.36▼ −3.99%▼ −4.21%$58.38 (−4.03%)
Aug 10, 2026
7w ago
Press Release
BEARISH ★ 7/10
$51.33 $53.10▼ −3.44%▼ −3.85%$58.38 (−13.73%)
Jun 3, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$52.39 $53.50▲ +2.12%▲ +4.68%$58.38 (+11.44%)
May 29, 2026
17w ago
8-K
NEUTRAL ★ 3/10
$50.20 $52.70▲ +4.98%▲ +7.73%$58.38 (+16.30%)
May 28, 2026
18w ago
Insider Cluster
NEUTRAL ★ 3/10
$50.32 $51.60▲ +2.55%▲ +2.84%$58.38 (+16.02%)
May 28, 2026
18w ago
Insider Cluster
NEUTRAL ★ 3/10
$50.32 $51.60▲ +2.55%▲ +2.84%$58.38 (+16.02%)
May 28, 2026
18w ago
Insider Cluster
NEUTRAL ★ 3/10
$50.32 $52.69▲ +4.71%▲ +7.23%$58.38 (+16.02%)
May 22, 2026
18w ago
Insider Cluster
NEUTRAL ★ 3/10
$49.94 $48.49▼ −2.90%▼ −4.12%$58.38 (+16.90%)
May 19, 2026
19w ago
Insider Cluster
NEUTRAL ★ 3/10
$49.89 $51.46▲ +3.15%▲ +1.34%$58.38 (+17.02%)
May 7, 2026
21w ago
Insider Cluster
NEUTRAL ★ 2/10
$46.10 $51.29▲ +11.26%▲ +9.76%$58.38 (+26.64%)
Showing 10 of 12

US Market Status

Market Open — Closes in 6h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access